Journal of Microbiology and Biotechnology, Journal Year: 2024, Volume and Issue: 34(8), P. 1698 - 1704
Published: July 12, 2024
Language: Английский
Heliyon, Journal Year: 2024, Volume and Issue: 10(15), P. e35336 - e35336
Published: July 27, 2024
Gastrointestinal (GI) cancers represent a significant global health challenge, driving relentless efforts to identify innovative diagnostic and therapeutic approaches. Recent strides in microbiome research have unveiled previously underestimated dimension of cancer progression that revolves around the intricate metabolic interplay between GI host's gut microbiota. This review aims provide comprehensive overview these emerging interactions their potential catalyze paradigm shift precision diagnosis breakthroughs cancers. The article underscores groundbreaking impact on oncology by delving into symbiotic connection host metabolism It offers valuable insights tailoring treatment strategies individual patients, thus moving beyond traditional one-size-fits-all approach. also sheds light novel methodologies could transform early detection cancers, potentially leading more favorable patient outcomes. In conclusion, exploring microbiota showcases promising frontier ongoing battle against formidable diseases. By comprehending harnessing microbiome's influence, future innovation for appears optimistic, opening doors tailored treatments enhanced precision.
Language: Английский
Citations
4
Nutrients, Journal Year: 2024, Volume and Issue: 16(16), P. 2644 - 2644
Published: Aug. 10, 2024
Breast cancer (BC) is one of the most common cancers worldwide and a leading cause cancer-related deaths among women. The escalating incidence BC underscores necessity multi-level treatment. complex heterogeneous disease involving many genetic, lifestyle, environmental factors. Growing evidence suggests that nutrition intervention an evolving effective prevention treatment strategy for BC. In addition, human microbiota, particularly gut now widely recognized as significant player contributing to health or status. It also associated with risk development This review will focus on in BC, including dietary patterns, bioactive compounds, nutrients affect therapeutic responses both animal studies. Additionally, this paper examines impacts these interventions modulating composition functionality microbiome, highlighting microbiome-mediated mechanisms combination factors microbes discussed. Insights from emphasize comprehensive management focuses nutrition–microbiome axis.
Language: Английский
Citations
4
JDDG Journal der Deutschen Dermatologischen Gesellschaft, Journal Year: 2025, Volume and Issue: 23(1), P. 104 - 107
Published: Jan. 1, 2025
Sehr geehrte Herausgeber, Eine Minderheit der Patienten mit lokal fortgeschrittenem Basalzellkarzinom (laBCC, locally advanced basal cell carcinoma) benötigt eine Behandlung Hedgehog-Signalweg-Inhibitoren (HhIs, Hedgehog pathway Inhibitors).1 Sonidegib ist letzte zugelassene HhI für BCC.2 Obwohl sich in Haut stärker anreichert und die Plasmakonzentration niedriger als bei anderen HhIs, können gastrointestinale Nebenwirkungen seine Verträglichkeit beeinträchtigen.1 Darüber hinaus hat den letzten Jahren herausgestellt, dass das Darmmikrobiom Schlüsselrolle Onkologie spielt, da verschiedene Neoplasmen spezifische Darmmikrobiomsignaturen aufweisen Ansprechen auf Immuntherapie Biodiversität des Mikrobioms zusammenhängt.3, 4 wurde Hedgehog-Signalweg Differenzierung gastroenterologischer Zellen Modulation Verbindung gebracht.5, 6 Ziel dieser Studie war es, festzustellen, ob Zusammensetzung Darmmikrobioms von laBCC gesunder Kontrollpersonen unterscheidet, mögliche bakterielle Biomarker Krankheit, zu untersuchen. Wir haben prospektive durchgeführt, zehn 15 alterskontrollierte gesunde aufgenommen wurden. Die örtlichen Ethikkommission genehmigt. Stuhlproben wurden Beginn nach Monaten ununterbrochener Sonidegib-Behandlung (200 mg täglich) entnommen. Es Next-Generation-Sequenzierung V3-V4-Region 16S rRNA-Gens durchgeführt. Ausschlusskriterien waren Verwendung systemischer Immunmodulatoren oder Antibiotika, extreme Diäten, Schwangerschaft, Einnahme Präbiotika Probiotika vorangegangenen 12 Wochen. Verzerrungskorrektur analysiert, um unterschiedliche Häufigkeit Darmbakterien zwischen Kontrollen bestimmen.7 Das Durchschnittsalter betrug 73,2 Jahre (Standardabweichung [SD] 4,8); sechs weiblich. Sechs zeigten ein teilweises Rest vollständiges Behandlung. An unerwünschten Wirkungen traten zwei Dysgeusie, einem Haarausfall erhöhte Leberenzyme auf. Mit Hilfe multivariaten Permutationsanalyse Varianz statistisch signifikante Unterschiede (p = 0,0017) Beta-Biodiversität Darmmikrobiota im Vergleich festgestellt (Abbildung 1). Alpha-Biodiversität (Shannon-Diversitätsindex) unabhängig Alter Geschlecht. Abbildung 2 zeigt relative Population wichtigsten Bakteriengattungen Darmmikrobiota. wiesen Werte Enterococcus sp., Eggerthella sp. Methanobrevibacter Gesunde Probanden hatten deutlich Lachnospiraceae. insgesamt weder Artenreichtum noch einzelner Taxa signifikant beeinflusste, alle Zunahme Zahl Lachnospiraceaen Darm 3). kein bakterieller gefunden, einer Wirkung gebracht wurde, Ausnahme Hepatitis, dem Lachnospiraceae wurde. vier geringsten vollständige Reaktion. Ergebnisse belegen, charakteristische mikrobiologische Signatur aufweisen, was einen Zusammenhang Darmmikrobita Hautkrebs analog extraintestinalen soliden Tumoren wie Brustkrebs hindeutet.3 Sonic (SHH)-Signalübertragung an Entwicklung Darms Homöostase Erwachsenen beteiligt möglicherweise beeinflusst, scheint keine umfassenden Auswirkungen biologische Vielfalt haben. Hervorzuheben auch Rolle Familie unerwünschte Wirkungen, Medikamente Krankheitsstatus. Ihre Beziehung zur Gesundheit Wirts nicht vollständig geklärt, Studien kontroverse sowohl Krankheit gezeigt haben.8 angereicherte Lebererkrankungen gebracht,9 durch intestinale Permeabilität erklärt wird.8 Interessanterweise wies Patient, Hepatitis entwickelte, größte Menge Lachnospiracea peripheren Reifung regulatorischer T-Lymphozyten Produktion kurzkettiger Fettsäuren (SCFAs, short-chain fatty acids) Butyrat beteiligt,8 physiologische Tumorkontrolle auswirken kann 10 ihr erhöhtes Vorkommen erklären könnte. allen verzeichnen war, es bemerkenswert, mikrobiellen Reaktion zeigten. Dies deutet darauf hin, wahrscheinlich über direkten Mechanismus wirkt, regulierten Immunität. Außerdem gibt Schwellenwerte, denen Mikrobiota negative (wie Hepatitis), neutrale positive (zum Beispiel antineoplastische) Wirt hat.10 Dennoch könnte Pharmakokinetik beeinflussen, indem sie Verfügbarkeit Aufnahme verändert, Wirksamkeit kann. Trotz Einschränkung, diese explorativ kleiner Stichprobe ist, öffnen ihre Tür Untersuchung nichtmelanozytärem Hautkrebs. Diese Sun Pharma finanziert. Keiner.
Citations
0
Microbiome Research Reports, Journal Year: 2025, Volume and Issue: 4(1)
Published: Feb. 27, 2025
Microbial communities inhabiting various body sites play critical roles in the initiation, progression, and treatment of cancer. The gut microbiota, a highly diverse microbial ecosystem, interacts with immune cells to modulate inflammation surveillance, influencing cancer risk therapeutic outcomes. Local tissue microbiota may impact transition from premalignant states malignancy. Characterization intratumoral increasingly reveals distinct microbiomes that influence tumor growth, responses, efficacy. Various bacteria species have been reported therapies through mechanisms such as altering drug metabolism shaping microenvironment (TME). For instance, or bacterial enzymatic activity can convert prodrugs into active forms, enhancing effects or, conversely, inactivating small-molecule chemotherapeutics. Specific also linked improved responses immunotherapy, underscoring microbiome’s role Furthermore, unique signatures patients, compared healthy individuals, demonstrate diagnostic potential microbiota. Beyond gut, tumor-associated local affect therapy by inflammation, resistance. This review explores multifaceted relationships between cancer, focusing on their modulating TME, activation, members represents promising avenue for advancing precision oncology improving patient By leveraging biomarkers interventions, new strategies be developed optimize diagnosis treatment.
Language: Английский
Citations
0
Cancers, Journal Year: 2025, Volume and Issue: 17(6), P. 940 - 940
Published: March 10, 2025
Exosomes have emerged as pivotal players in precision oncology, offering innovative solutions to longstanding challenges such metastasis, therapeutic resistance, and immune evasion. These nanoscale extracellular vesicles facilitate intercellular communication by transferring bioactive molecules that mirror the biological state of their parent cells, positioning them transformative tools for cancer diagnostics therapeutics. Recent advancements exosome engineering, artificial intelligence (AI)-driven analytics, isolation technologies are breaking barriers scalability, reproducibility, clinical application. Bioengineered exosomes being leveraged CRISPR-Cas9 delivery, while AI models enhancing biomarker discovery liquid biopsy accuracy. Despite these advancements, key obstacles heterogeneity populations lack standardized protocols persist. This review synthesizes pioneering research on biology, molecular translation, emphasizing dual roles both mediators tumor progression intervention. It also explores emerging areas, including microbiome–exosome interactions integration machine learning exosome-based medicine. By bridging innovation with translational strategies, this work charts a forward-looking path integrating into next-generation care, setting it apart comprehensive guide overcoming technological hurdles rapidly evolving field.
Language: Английский
Citations
0
Journal of Food Composition and Analysis, Journal Year: 2025, Volume and Issue: unknown, P. 107495 - 107495
Published: March 1, 2025
Language: Английский
Citations
0
Journal of Personalized Medicine, Journal Year: 2025, Volume and Issue: 15(4), P. 124 - 124
Published: March 24, 2025
Background: Hepatobiliary liver cancers (HBLCs) represent the sixth most common neoplasm in world. Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) constitute main HBLC types, with alarming epidemiological projections. Methods: In recent decades, alterations gut microbiota, mutual implications on gut–liver axis gut–biliary permeability status, have been massively investigated proposed as pathogenetic deus ex machina. Results: HCC setting, elevated intestinal levels of Escherichia coli other Gram-negative bacteria demonstrated, resulting a close association increased lipopolysaccharide (LPS) serum and, consequently, chronic systemic inflammation. contrast, microbiota individuals feature reduced Lactobacillus spp., Bifidobacterium Enterococcus spp. CC evidence has revealed an expression enhanced Actynomices Alloscardovia Besides impaired strains/species representation, gut-derived metabolites, including bile acids (BAs), short-chain fatty (SCFAs), oxidative-stress-derived products, configure network severely impacting progression HBLC. Conclusions: era Precision Medicine, clarification composition functioning settings can contribute to identification individual signatures, potentially providing novel diagnostic markers, therapeutic approaches, prognostic/predictive tools.
Language: Английский
Citations
0
Technology in Cancer Research & Treatment, Journal Year: 2025, Volume and Issue: 24
Published: April 1, 2025
This review summarizes the intricate relationship between microbiome and cancer initiation development. Microbiome alterations impact metabolic pathways, immune responses, gene expression, which can accelerate or mitigate progression. We examine how dysbiosis affects tumor growth, metastasis, treatment resistance. Additionally, we discuss potential of microbiome-targeted therapies, such as probiotics fecal microbiota transplants, to modulate metabolism. These interventions offer possibility reversing controlling progression, enhancing efficacy traditional treatments like chemotherapy immunotherapy. Despite promising developments, challenges remain in identifying key microbial species pathways validating therapies through large-scale clinical trials. Nonetheless, intersection research development presents an exciting frontier for innovative therapies. offers a fresh perspective on by integrating insights, highlighting interdisciplinary enhance our understanding progression strategies.
Language: Английский
Citations
0
Advances in clinical chemistry, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 1, 2025
Language: Английский
Citations
0
Gut Microbes, Journal Year: 2025, Volume and Issue: 17(1)
Published: April 20, 2025
The pathogenesis of cancer is closely related to the disruption homeostasis in human body. gut microbiome plays crucial roles maintaining its host throughout lifespan. In recent years, a large number studies have shown that dysbiosis involved entire process initiation, development, and prognosis by influencing immune system metabolism. Some specific intestinal bacteria promote occurrence development cancers under certain conditions. Conversely, some other suppress oncogenesis progression cancers, including inhibiting delaying boosting therapeutic effect on cancers. promoting effects been comprehensively discussed previous review. This article will review latest advances mechanisms suppression, providing new perspective for developing strategies prevention treatment.
Language: Английский
Citations
0